CV: רווח למניה בשנים עשר החודשים האחרונים CapsoVision, Inc.
CapsoVision Inc is expanding its presence in the GI imaging segment by offering a painless alternative to endoscopy with a 360° view. The annual EPS TTM slice reflects the dynamics of these processes, where -0.62 forms the current metric value. Growth is protected by microelectronics patents, while stringent FDA requirements and physician conservatism create significant barriers to entry for new players.
פילוחי מדדים ואנליטיקה של חברת CapsoVision, Inc. (CV)
This indicator measures the aggregate net income over the last twelve months distributed per share and adjusted for the volume of issuance, allowing for an objective assessment of the actual return on capital. Amid stringent FDA certification and clinical validation costs for capsule endoscopy, the fundamental net income per share TTM for CapsoVision Inc (CV) demonstrates the efficiency of patent monetization, confirming the resilience of the business model.
